相关实验视频
Updated: Jun 11, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
通过口服血小板糖蛋白IIb/IIIa抗剂增加死亡率:第三期多中心随机试验的元分析
1Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Circulation
|February 24, 2001
概括
口服糖蛋白IIb/IIIa抑制剂在冠状动脉疾病管理中增加了死亡风险,尽管减少了急需的再血管化需求. 需要进一步的研究来了解与这些抗血小板剂相关的死亡风险增加.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 静脉注射的葡萄糖蛋白IIb/IIIa抑制剂对冠状动脉疾病有益.
- 口服糖蛋白IIb/IIIa对抗剂在大型试验中没有显示出可比的益处.
- 口服药物的血小板聚合抑制并没有转化为减少缺血事件.
研究的目的:
- 评估口服糖蛋白IIb/IIIa抑制剂的安全性和有效性.
- 分析口服糖蛋白IIb/IIIa对抗剂的大规模,安慰剂对照试验的结果.
- 调查这些药物对死亡率,心肌梗塞和重血管化的影响.
主要方法:
- 对4项大规模,安慰剂控制,随机化试验的综合分析.
- 包括33326名患者,随访时间>30天.
- 根据治疗剂量和阿司匹林使用情况,计算和分层对关键临床终点的几率比率 (OR),包括死亡率,心肌梗塞,紧急重血管化和严重出血.
主要成果:
- 通过口服糖蛋白IIb/IIIa治疗观察到死亡率的统计显著增加 (OR,1.37;P:=0.001).
- 这种增加的死亡风险在不同的药物,剂量以及与阿司匹林或没有阿司匹林之间是一致的.
- 紧急重血管化的减少被注意到,但没有发现心肌梗塞的显著增加.
结论:
- 口服葡萄糖蛋白IIb/IIIa抑制剂与死亡率显著增加有关.
- 观察到的死亡率增加可能表明直接的毒性作用,而不是原血栓机制.
- 需要进一步调查以确定这些药物增加的死亡风险的原因.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

